Hormonal therapy for prostate cancer: past, present and future
Authors:
- Maha H HussainMHMaha H Hussain
- 1 February 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 2 (1) , 37-47
Abstract
Prostate cancer is the second leading cause of cancer mortality in men in the USA. For the past six decades, hormonal therapy has been the main treatment of advanced prostate cancer. Hormonal therapy has developed from a surgical procedure to a complex pharmacological treatment. Trials comparing the efficacy of different monotherapies have demonstrated the equivalence of DES, LHRH agonists and orchiectomy. Combined androgen blockade has been compared with monotherapy. However, the results of the different trials have been conflicting. Novel hormonal therapy schedules involving intermittent treatment and peripheral androgen blockade are currently in clinical trials. The role of hormonal therapy in locally advanced disease as part of a multimodality therapy is a new and rapidly developing aspect of hormonal therapy. The mechanism of hormone refractoriness in prostate cancer is an active area of basic science and translational research.Keywords
This publication has 11 references indexed in Scilit:
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000
- Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancerUrology, 1997
- Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate CancerJournal of Urology, 1996
- Intermittent androgen suppression in the treatment of prostate cancer: A preliminary reportUrology, 1995
- Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndromeUrology, 1994
- Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer, 1993
- Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell linesThe Prostate, 1993
- Testosterone at High Concentrations Interacts with the Human Androgen Receptor Similarly to Dihydrotestosterone*Endocrinology, 1990
- Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methodsJournal of Endocrinology, 1987
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983